Research Article

Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt

Figure 1

Frequencies of remission (a) and EULAR response (b) at 6 months according to biologic treatment. Tocilizumab- (TCZ-) treated patients had higher rates of DAS28 remission and EULAR response. Similar proportions of TCZ and TNFi users were in remission according to CDAI, SDAI, and Boolean remission criteria. value significant at <0.05. ADA: adalimumab; ETA: etanercept; GOLI: golimumab; INF: infliximab.
(a)
(b)